0A3S.LSE Novavax Inc.

Healthcare Commercial Services & Supplies London Exchange
- USD
Market cap
-
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2023.

Is 0A3S.LSE undervalued?

Graham number

The Graham number of Novavax Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Novavax Inc. fundamental analysis

No fundamental analysis for Novavax Inc. yet.

Novavax Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Novavax Inc.

Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, a…

Full company profile